Lorlatinib is a specialized third-gen ALK and ROS1 kinase inhibitor for treating tough lung cancer when other ALK drugs don’t work anymore. So, it’s like one of those kinase inhibitors that target cancer cell enzymes to stop them from growing and multiplying. Lorlatinib tackles those ALK and ROS1 kinases that push tumors to grow more, and blocks ’em out.
Lorlatinib comes in two dosages—25mg and 100mg—and both are these tablets with a coating. The usual dose for grown-ups is just one 100mg tablet each day, you can take it with or without food. Each bottle’s got 30 tablets of Lorlatinib.
It’s used along with other treatments if you’ve already had trouble with ALK inhibitors, especially in advanced NSCLC with a positive ALK. Health providers and patients gotta keep an eye out for any side effects and see how the treatment’s working with lorlatinib or any cancer drug, basically.
